Sandra Eketorp Sylvan

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: BLOOD ADVANCES. 2025;9(13):3170-3181
Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: focus on the very early period and Omicron era
Hedberg P; Blixt L; Sylvan SE; Moller IK; Lindahl H; Kahn F; Nilsdotter-Augustinsson A; Fredrikson M; Nystrom S; Bergman P; Carlander C; Aleman S; Osterborg P; Osterborg A; Hansson L
Article: INFECTIOUS DISEASES. 2025;57(2):178-191
Risk of COVID-19 hospitalisation by HIV-status and SARS-CoV-2 vaccination status during pre- and post-Omicron era in a national register-based cohort study in Sweden
Killander Moeller I; Hedberg P; Wagner P; Lindahl H; Nystroem S; Blixt L; Eketorp Sylvan S; Nilsdotter-Augustinsson A; Oesterborg A; Fredrikson M; Hansson L; Kahn F; Sparen P; Gisslen M; Naucler P; Bergman P; Aleman S; Carlander C
Article: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2025;155(2):387-397.e6
Inborn errors of immunity are associated with increased COVID-19-related hospitalization and intensive care compared to the general population
Lindahl H; Kahn F; Nilsdotter-Augustinsson A; Fredrikson M; Hedberg P; Moeller IK; Hansson L; Blixt L; Sylvan SE; Osterborg A; Aleman S; Carlander C; Nilsdotter-Augustinsson A; Nystrom S; Bergman P
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;111(5):715-721
Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients
Mattsson A; Sylvan SE; Axelsson P; Ellin F; Kjellander C; Larsson K; Lauri B; Lewerin C; Scharenberg C; Tatting L; Johansson H; Osterborg A; Hansson L
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;191(3):426-432
Risk-adapted bendamustine plus rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients
Mattsson A; Sylvan SE; Asklid A; Wiggh J; Winqvist M; Lundin J; Mansouri L; Rosenquist R; Johansson H; Osterborg A; Hansson L
Article: LEUKEMIA & LYMPHOMA. 2020;61(9):2136-2144
A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy
Asklid A; Sylvan SE; Mattsson A; Winqvist M; Johansson H; Osterborg A; Hansson L
Article: HAEMATOLOGICA. 2019;104(4):797-804
FFirst-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
Sylvan SE; Asklid A; Johansson H; Klintman J; Bjellvi J; Tolvgard S; Kimby E; Norin S; Andersson P-O; Karlsson C; Karlsson K; Lauri B; Mattsson M; Sandstedt AB; Strandberg M; Osterborg A; Hansson L
Article: ANNALS OF HEMATOLOGY. 2017;96(10):1681-1691
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
Hansson L; Asklid A; Diels J; Eketorp-Sylvan S; Repits J; Soltoft F; Jaeger U; Osterborg A
Journal article: LEUKEMIA & LYMPHOMA. 2017;58(5):1219-1223
Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013
Asklid A; Winqvist M; Sylvan SE; Mattsson A; Bjorgvinsson E; Soltoft F; Repits J; Diels J; Osterborg A; Hansson L
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2017;66(1):91-102
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
Winqvist M; Mozaffari F; Palma M; Sylvan SE; Hansson L; Mellstedt H; Osterborg A; Lundin J
Article: EXPERIMENTAL HEMATOLOGY. 2016;44(1):38-49.e1
Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative study
Sylvan SE; Skribek H; Norin S; Muhari O; Osterborg A; Szekely L
Article: ANNALS OF HEMATOLOGY. 2014;93(10):1725-1733
Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients
Sylvan SE; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
Article: LEUKEMIA & LYMPHOMA. 2014;55(8):1774-1780
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region
Sylvan SE; Hansson L; Karlsson C; Norin S; Lundin J; Osterborg A
Journal article: BRITISH JOURNAL OF HAEMATOLOGY. 2012;159(5):608-612
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression
Sylvan SE; Rossmann E; Mozaffari F; Porwit A; Norin S; Karlsson C; Hansson L; Lundin J; Osterborg A

Alla övriga publikationer

Doctoral thesis: 2014
Targeted therapy and outcome in chronic lymphocytic leukemia
Eketorp Sylvan S

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2024-2027

Examina och utbildning

Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2015
Läkarexamen, Karolinska Institutet, 2003

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI